Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤$120 million private placement completed alongside Prana Therapies acquisition
- ➤PRA-216 entered Phase 2 studies in asthma, atopic dermatitis and COPD
- ➤Initial PRA-216 data expected beginning in 2Q 2027 across four studies
- ➤Cash runway expected to fund operations into 2028
- ➤Third-quarter net loss narrowed to $4.4 million from $7.1 million
Expert Statements
Sheila Gujrathi, Chief Strategy Officer of Bolt Biotherapeutics
“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”
Sheila Gujrathi, Chief Strategy Officer of Bolt Biotherapeutics
“PRA-216 is our flagship program and the first clinical validation of the INSPIRE platform. It is now in Phase 2 development in asthma, COPD and atopic dermatitis, with an additional study planned in eosinophilic esophagitis, and we expect patient proof-of-concept data across all four studies beginning in the second quarter of 2027.”
Sheila Gujrathi, Chief Strategy Officer of Bolt Biotherapeutics
“These studies will evaluate the potential of PRA-216 to move beyond the efficacy ceiling of single-mechanism therapies by combining complementary IL-4Rα and TSLP inhibition, while offering the potential convenience of infrequent, at-home dosing.”
Sheila Gujrathi, Chief Strategy Officer of Bolt Biotherapeutics
“Beyond PRA-216, we look forward to advancing additional wholly owned programs from INSPIRE as we work to build a new generation of differentiated multispecific therapies.”
Willie Quinn, President and Chief Executive Officer of Bolt Biotherapeutics
“Completing the Prana acquisition marks an important transformation for Bolt.”
Willie Quinn, President and Chief Executive Officer of Bolt Biotherapeutics
“With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”
* Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus * Initiated Phase 2 studies with PRA-216, a half-life-extended IL-4Rα/TSLP bispecific, in asthma, atopic dermatitis and chronic obstructive pulmonary disease with initial data expected in 2Q 2027 * Recently disclosed PRA-216 Phase 1 data provided first clinical validation of PRA-216 and the proprietary INSPIRE multispecific antibody platform with the potential for at-home maintenance dosing every 8 to 12 weeks; a second wholly owned INSPIRE program is expected to enter the clinic and generate initial clinical data in 2H 2027 * Cash runway expected to fund operations into 2028 through multiple clinical and preclinical milestones REDWOOD CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company advancing next-generation, half-life-extended multispecific antibodies, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.